Johnson & Johnson Impresses with Earnings Beat, Dividend Hike, and Bullish Analyst Target

Johnson & Johnson (NYSE:JNJ) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In.

Following a strong positive quarter, the company witnesses a rise in price target and announces new data on its pill.

Johnson & Johnson (NYSE: JNJ) reported an EPS of $2.77 for the second quarter of 2025 on July 16, 2025, successfully surpassing the consensus analyst estimate of $2.68. Similarly, the company’s revenue of $23.74 billion for the quarter exceeded analyst expectations of $22.85 billion, signaling a good performance amid a complex economic environment. The company’s board has also declared a quarterly cash dividend of $1.30 per share, representing a 63rd consecutive annual dividend increase and a growth from the previous quarter’s rate of $1.24 per share.

Following the strong quarter, JP Morgan raised the stock’s price target from $185 to $195 while keeping a Neutral rating. Additionally, the company announced new data from the Phase 3 Iconic-Advance 1 and 2 studies on icotrokinra, which hints at the superiority of the pill to deucravacitinib and placebo in treating moderate-to-severe plaque psoriasis.

Holding on to this positive outlook, Johnson & Johnson (NYSE:JNJ) offers a dividend yield of 2.95% attracting investors looking for a stable income.

The American multinational corporation, Johnson & Johnson (NYSE:JNJ), was founded in 1886. Headquartered in New Jersey, the company is a global leader in the healthcare industry, specializing in the development of pharmaceuticals and consumer health products.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Performing IPOs in the Last 2 Years and 12 Jim Cramer Stock Picks this Week

Disclosure. None.